[Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity

Rhea-AI Filing Summary

Corcept Therapeutics officer Sean Maduck, President of Corcept Endocrinology, reported several indirect ownership changes in Corcept common stock dated January 8, 2026. Entities associated with him made bona fide gifts of 20,570 and 34,000 shares held indirectly through the Sean and Molly Maduck Living Trust and a related trust, each at a stated price of $0.00 per share. Corresponding entries show 20,570 shares held by MMM 2025, LLC and 34,000 shares held by the SNM 2026 Grantor Retained Annuity Trust, both entities associated with Maduck. He also reports 8,179 shares held directly, which include unvested restricted stock awards scheduled to vest one year after their respective grant dates if service conditions are met, plus additional indirect holdings through another grantor retained annuity trust and Duckhill Capital, LLC.

Insider Trade Summary

54,570 shares gifted

Mixed 7 txns

Insider Maduck Sean

Role See Remarks

Type	Security	Shares	Price	Value
Gift	Common Stock	20,570	$0.00	--
Other	Common Stock	20,570	$0.00	--
Gift	Common Stock	34,000	$0.00	--
Other	Common Stock	34,000	$0.00	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 39,147 shares (Indirect, See Footnote); Common Stock — 8,179 shares (Direct)

Footnotes (1)

1. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager. Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee. Includes 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 228 underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 205 underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Maduck Sean

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/08/2026		G		20,570	D	$0.00	39,147	I	See Footnote(1)
Common Stock	01/08/2026		J		20,570	A	$0.00	20,570	I	See Footnote(2)
Common Stock	01/08/2026		G		34,000	D	$0.00	5,147	I	See Footnote(1)
Common Stock	01/08/2026		J		34,000	A	$0.00	34,000	I	See Footnote(3)
Common Stock								8,179(4)	D
Common Stock								40,000	I	See Footnote(5)
Common Stock								10,000	I	See Footnote(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.

2. Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.

3. Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.

4. Includes 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 228 underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 205 underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

5. Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.

6. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

Remarks:

President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.